NCT04051268
Completed
Phase 3
Immunogenicity and Safety of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults, Children and Infants, Lot to Lot Consistency, Non-inferiority to PQed (Prequalified) TCV (Typhoid Conjugate Vaccine)
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Safety Issues
- Sponsor
- PT Bio Farma
- Enrollment
- 3071
- Locations
- 1
- Primary Endpoint
- Immunogenicity
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Phase III study, Randomized, observer blind, lot to lot consistency, non inferiority to PQed typhoid conjugate vaccine and Typhoid Vi polysaccharide vaccine.
Detailed Description
Phase III study, Randomized, observer blind, lot to lot consistency, non inferiority to PQed typhoid conjugate vaccine and to Typhoid Vi polysaccharide vaccine. Involved participants aged 6 months old to 60 years old.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject/Parents/legal guardian(s) have been informed properly regarding the study and signed the informed consent form/and informed assent form.
- •Subject/parents/legal guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial.
Exclusion Criteria
- •Subject concomitantly enrolled or scheduled to be enrolled in another trial.
- •Evolving mild, moderate or severe illness, especially infectious diseases or fever (axilary temperature ³ 37.5°C).
- •Known history of allergy to any component of the vaccines.
- •History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection.
- •Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, corticosteroid therapy and other immunosuppressants)
- •Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
- •Pregnancy \& lactation (Adults).
- •Individuals who have previously received any vaccines against typhoid fever.
- •Subjects already vaccinated with any vaccine within one month prior and expect to receive other vaccines within one month following vaccination except MR (Measles Rubella) vaccine.
- •Individuals who have a previously ascertained typhoid fever by laboratory confirmation (blood culture/new rapid test) at any time.
Outcomes
Primary Outcomes
Immunogenicity
Time Frame: 28 days
Seroconversion following vaccination with one dose of Vi-DT (Bio Farma) in adults, children and infants.
Secondary Outcomes
- Describe antibody response following vaccination(28 days)
- Adverse event, solicited or unsolicited(28 days)
- Comparison the safety and immunogenicity(28 days)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and InfantsSafety IssuesImmunogenicityNCT03460405PT Bio Farma600
Not Yet Recruiting
Phase 3
ZyVac-TCV Bangladesh StudyTyphoid VaccinationTyphoidTyphoid FeverNCT06757283International Centre for Diarrhoeal Disease Research, Bangladesh4,000
Completed
Phase 2
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy AdultsTyphoidNCT00679172Emergent BioSolutions187
Completed
Phase 4
A clinical trial to study the optimal use of conjugate typhoid vaccine- Single dose vs two doses.CTRI/2010/091/003031DR. Balaji Chinnasami,No.5, Adhilaxmi Flats, Balaji Street, Rajaji Nagar, Villivakkam, Chennai-49Phone- 9445482710e-mail: balajictriumphants@gmail.com400
Active, Not Recruiting
Phase 3
Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, MalawiTyphoidNCT03299426University of Maryland, Baltimore30,000